Contineum Therapeutics, Inc. (CTNM)
| Market Cap | 397.32M |
| Revenue (ttm) | 50.00M |
| Net Income (ttm) | 3.15M |
| Shares Out | 25.13M |
| EPS (ttm) | 0.08 |
| PE Ratio | 197.63 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,831 |
| Open | 16.00 |
| Previous Close | 16.02 |
| Day's Range | 15.70 - 16.02 |
| 52-Week Range | 13.27 - 16.09 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 28.00 (+77.1%) |
| Earnings Date | May 20, 2024 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 77.10% from the latest price.
News
Contineum Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule ther...
Neuroscience and inflammation biotech Contineum Therapeutics files for a $150 million IPO
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for NI&I indications, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
Contineum Therapeutics IPO Registration Document (S-1)
Contineum Therapeutics has filed to go public with an IPO on the NASDAQ.